By City: Aberdeen • Aberdeen and Stockton on Tees • Amersham • Banchory • Bristol • Cobham • Croydon • Darlington • Dundee • Dunfermline • Durham • Edinburgh • Glasgow • Godalming • Grangemouth • Guildford • Hayling Island • Huntly • Kinross • Kinross, Perth & Kinross • Levens • London • Manchester • Middlebrough • Montrose • Newbury • Paris • Perth • Rossy Charles de Gaulle Cedex • Sevenoaks • South Queensferry • Wallingford • Westhill • Yateley, Hampshire • Zug •
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that ELIQUIS will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2011, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.